Vivus (VVUS.Q) jumps 47% after FDA approval of improved Pancreaze pancreatic medication

Chris Parry
February 5, 2020
If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there. For the high risk, high reward investor, nothing is quite like the thrill of correctly picking when a long, drawn out, US Food and Drug Administration process of approving a new drug finally gets over the line.